Alunbrig is owned by Takeda Pharms Usa.
Alunbrig contains Brigatinib.
Alunbrig has a total of 4 drug patents out of which 0 drug patents have expired.
Alunbrig was authorised for market use on 28 April, 2017.
Alunbrig is available in tablet;oral dosage forms.
Alunbrig can be used as treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc).
Drug patent challenges can be filed against Alunbrig from April, 2021.
The generics of Alunbrig are possible to be released after 10 November, 2035.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9012462 | TAKEDA PHARMS USA | Phosphorous derivatives as kinase inhibitors |
Apr, 2031
(8 years from now) | |
US10385078 | TAKEDA PHARMS USA | Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine |
Nov, 2035
(12 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9273077 | TAKEDA PHARMS USA | Phosphorus derivatives as kinase inhibitors |
May, 2029
(6 years from now) | |
US9611283 | TAKEDA PHARMS USA | Methods for inhibiting cell proliferation in ALK-driven cancers |
Apr, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 28, 2022 |
Orphan Drug Exclusivity (ODE) | May 22, 2027 |
New Indication (I) | May 22, 2023 |
Drugs and Companies using BRIGATINIB ingredient
NCE-1 date: April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic